SNDX-4321
/ Syndax Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 14, 2026
Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs
(Syndax Press Release)
- "The Company expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027."
IND • New P1 trial • Non Small Cell Lung Cancer
1 to 1
Of
1
Go to page
1